Hubei Jumpcan Pharmaceutical Co., Ltd. (SHA:600566)
China
· Delayed Price · Currency is CNY 27.52
+0.80 (2.99%)
Apr 29, 2026, 3:00 PM CST
SHA:600566 Revenue
Hubei Jumpcan Pharmaceutical had revenue of 1.21B CNY in the quarter ending March 31, 2026, a decrease of -20.84%. This brings the company's revenue in the last twelve months to 5.90B, down -17.35% year-over-year. In the year 2025, Hubei Jumpcan Pharmaceutical had annual revenue of 6.22B, down -22.43%.
Revenue (ttm)
5.90B
Revenue Growth
-17.35%
P/S Ratio
4.17
Revenue / Employee
1.17M
Employees
5,026
Market Cap
24.63B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.22B | -1.80B | -22.43% |
| Dec 31, 2024 | 8.02B | -1.64B | -16.96% |
| Dec 31, 2023 | 9.65B | 658.17M | 7.32% |
| Dec 31, 2022 | 9.00B | 1.37B | 17.90% |
| Dec 31, 2021 | 7.63B | 1.47B | 23.77% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Kangmei Pharmaceutical | 5.25B |
| Zhejiang Huahai Pharmaceutical | 8.71B |
| Dizal (Jiangsu) Pharmaceutical | 801.14M |
| Jiangsu Nhwa Pharmaceutical Co., LTD | 6.01B |
| Livzon Pharmaceutical Group | 11.71B |
| Tasly Pharmaceutical Group | 8.35B |
| Chengdu Kanghong Pharmaceutical Group | 4.43B |
| Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd | 1.17B |